Julie Daves

Equibles does not estimate personal net worth.

About Julie Daves

DiaMedica Therapeutics Inc. reported in an 8-K filed April 10, 2024 that Julie Daves resigned as Senior Vice President, Clinical Development Operations, effective April 18, 2024. The proxy statement of DiaMedica Therapeutics Inc. reports total compensation of $533,370 for Julie Daves in fiscal 2023, including a base salary of $306,754.

“On April 5, 2024, Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. ("DiaMedica"), effective as of April 18, 2024, for personal reasons.”

DiaMedica Therapeutics Inc. Form 8-K, filed April 10, 2024 · Read the filing

Affiliation history

DiaMedica Therapeutics Inc. (DMAC)
Proxy statement

Start not stated–2024-04-18

Company network

DiaMedica Therapeutics Inc.

DMAC

Biotechnology · Healthcare

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2023	DiaMedica Therapeutics Inc. (DMAC)	SVP, Clinical Development Operations	$306,754	—	—	$118,309	$91,657	$16,650	$533,370

Recent activity

Executive change Resigned: Senior Vice President, Clinical Development Operations DiaMedica Therapeutics Inc. (DMAC)
2024-04-18